Your email has been successfully added to our mailing list.

×
0 0 0 0 0.0659340659340661 0.0659340659340661 0.0659340659340661 0.0659340659340661
Stock impact report

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

Telix Pharmaceuticals Limited - American Depositary Shares (TLX) 
Company Research Source: GlobeNewswire
MELBOURNE, Australia and INDIANAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers: Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in Salt Lake City, UT, will discuss the ProstACT Global Phase 3 trial of TLX591 (177Lu rosopatamab tetraxetan), Telix’s lead radio antibody-drug conjugate (rADC Read more
Impact Snapshot
Event Time:
TLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Created with Highstock 5.0.1230sec1m5m10m30m60m90m120m0.00%2.50%5.00%7.50%
Opt-in for TLX alerts
Opt-in for
TLX alerts

from News Quantified
Opt-in for
TLX alerts

from News Quantified